Immunic Therapeutics

Biotechnology, Life Science, Medical, Therapeutics

Founded in 4/1/16

New York, New York, United States

http://www.imux.com

For Profit

About Immunic Therapeutics

Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Company Metrics

Employees: 11-50
Monthly Visits: 5016
Tech Stack: None active products

Financial Information

Estimated Revenue: Less than $1M
Total Funding: 284363541 USD
Last Funding: 60000000 USD (Post-IPO Equity)
Funding Status: IPO

Technology Stack

Immunic Therapeutics actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Life Science, Medical, Therapeutics

Headquarters: New York, New York, United States

Employees